SG11201805385QA - Bromodomain and extra-terminal protein inhibitor combination therapy - Google Patents

Bromodomain and extra-terminal protein inhibitor combination therapy

Info

Publication number
SG11201805385QA
SG11201805385QA SG11201805385QA SG11201805385QA SG11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA SG 11201805385Q A SG11201805385Q A SG 11201805385QA
Authority
SG
Singapore
Prior art keywords
international
bromodomain
extra
bet
combination therapy
Prior art date
Application number
SG11201805385QA
Inventor
Zariana Nikolova
Robert Cho
Jeffrey Alan Stafford
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of SG11201805385QA publication Critical patent/SG11201805385QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 June 2017 (29.06.2017) WIPOIPCT (10) International Publication Number WO 2017/112703 A1 (51) International Patent Classification: A61P 35/00 (2006.01) A ft IK 9/00 (2006.01) A61K 31/337 (2006.01) G01N 33/574 (2006.01) (21) International Application Number: PCT/US2016/067860 (22) International Filing Date: 20 December 2016 (20.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/387,359 24 December 2015 (24.12.2015) US 62/413,763 27 October 2016 (27.10.2016) US (71) Applicant: CELGENE QUANTICEL RESEARCH, INC. [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, California 92121 (US). (72) Inventors: NIKOLOVA, Zariana; c/o Celgene Interna­ tional Sari, Route de Perreaux 1, 2017 Boudry (CH). CHO, Robert; 1585 Riorden Terrace, Sunnyvale, Califor­ nia 94087 (US). STAFFORD, Jeffrey Alan; 12752 Sandy Crest Court, San Diego, California 92130 (US). (74) Agents: SUNG, Lawrence M. et al.; Wiley Rein LLP, Pat­ ent Administration, 1776 K Street, NW, Washington, Dis­ trict of Columbia 20006 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY FIG. 8 o i> CJ 2500 ro £ 200 | 1500 :> £ IOOO c S 500 0 10 15 Days of Treatment 20 o CJ (57) : The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administra­ tion of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.
SG11201805385QA 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy SG11201805385QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387359P 2015-12-24 2015-12-24
US201662413763P 2016-10-27 2016-10-27
PCT/US2016/067860 WO2017112703A1 (en) 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy

Publications (1)

Publication Number Publication Date
SG11201805385QA true SG11201805385QA (en) 2018-07-30

Family

ID=59087538

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202013249PA SG10202013249PA (en) 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201805385QA SG11201805385QA (en) 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202013249PA SG10202013249PA (en) 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy

Country Status (16)

Country Link
US (1) US20170182025A1 (en)
EP (1) EP3393586A4 (en)
JP (1) JP2019503358A (en)
KR (1) KR20180095935A (en)
CN (1) CN108883311A (en)
AU (1) AU2016379347A1 (en)
BR (1) BR112018013063A2 (en)
CA (1) CA3009642A1 (en)
CL (1) CL2018001724A1 (en)
EA (1) EA201891514A1 (en)
IL (1) IL260222A (en)
MX (1) MX2018007823A (en)
SG (2) SG10202013249PA (en)
TW (1) TW201733576A (en)
WO (1) WO2017112703A1 (en)
ZA (1) ZA201804223B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102528406B1 (en) * 2016-10-27 2023-05-03 셀젠 콴티셀 리서치, 인크. Combination therapy with bromodomain and extra-terminal protein inhibitors
WO2019109057A1 (en) 2017-12-01 2019-06-06 The Board Of Trustees Of The University Of Illinois Pyridinone-based epigenetic modifiers and uses thereof
WO2019204758A1 (en) * 2018-04-20 2019-10-24 Zhiguo Zhang Compositions and methods for treating glioblastoma by modulating a mgmt enhancer
CN109001638B (en) * 2018-06-22 2020-12-29 格林美（无锡）能源材料有限公司 Method for rapidly evaluating DCR before and after coating of positive electrode material
EP3826992A2 (en) * 2018-07-23 2021-06-02 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
WO2020169698A1 (en) * 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
EP4025590A4 (en) * 2019-09-03 2024-01-03 Flagship Pioneering Innovations V Inc Methods and compositions for treating cancer
CN111930838B (en) * 2020-07-23 2023-05-16 金陵科技学院 Time-oriented distributed archive management method
WO2023087012A1 (en) * 2021-11-15 2023-05-19 The Board Of Trustees Of The University Of Illinois Method of treating cancer associated with a ras mutation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986962C (en) * 2012-07-13 2020-04-14 Becton Dickinson and Company Ltd. Medical vial access device with pressure equalization and closed drug transfer system and method utilizing same
WO2014080290A2 (en) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
TWI527811B (en) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 Benzimidazole derivatives as bromodomain inhibitors
PT3010503T (en) * 2013-06-21 2020-06-16 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
MX371386B (en) * 2013-10-18 2020-01-27 Celgene Quanticel Res Inc Bromodomain inhibitors.
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
JP2019503358A (en) 2019-02-07
BR112018013063A2 (en) 2018-12-11
TW201733576A (en) 2017-10-01
EA201891514A1 (en) 2019-01-31
EP3393586A1 (en) 2018-10-31
KR20180095935A (en) 2018-08-28
CL2018001724A1 (en) 2018-11-16
WO2017112703A1 (en) 2017-06-29
US20170182025A1 (en) 2017-06-29
CA3009642A1 (en) 2017-06-29
ZA201804223B (en) 2019-09-25
CN108883311A (en) 2018-11-23
IL260222A (en) 2018-07-31
EP3393586A4 (en) 2019-07-17
MX2018007823A (en) 2018-11-09
AU2016379347A1 (en) 2018-07-12
SG10202013249PA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201810171SA (en) Kras g12c inhibitors
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201806110QA (en) Treatment of cancer with combinations of immunoregulatory agents
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201808125RA (en) Methods for solid tumor treatment
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201809751XA (en) Egfr inhibitor compounds
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201408119PA (en) Systems and methods for data center cooling and water desalination
SG11201900486WA (en) Treatment and prevention of sleep disorders